FDA is freezing clinical development of an investigational cancer drug based on trial results presented at the American Society of Clinical Oncology June 3. Under the clinical hold, Telik stops treatment with Telcyta (canfosfamide) in trials after two studies in second-line advanced platinum refractory or resistant ovarian cancer and one study in third-line NSCLC failed to show benefit with treatment...
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.